What question did this study set out to answer?

To highlight the use of PSMA-targeted PET imaging in identifying prostate, hepatic, and osseous lesions in a patient with multiple concurrent cancers.

May 20, 2026Clinical nuclear medicine open.0 citationsOpen Access

Prostate, Hepatic, and Osseous Lesions on 18F-DCFPyL PET/CT

View Full Paper

SJSaurabh Jindal SMSayan Manna JKJames E. Kelly

Key Points

To highlight the use of PSMA-targeted PET imaging in identifying prostate, hepatic, and osseous lesions in a patient with multiple concurrent cancers.
Case report on a patient with synchronous malignancies confirmed via PSMA-targeted PET imaging.
Assessment of prostate, hepatic, and osseous lesions' PSMA avidity.
Identification of PSMA avid lesions in prostate, liver, and bones.
Findings complicating management and treatment decisions due to multiple malignancies.

Abstract

Prostate-specific membrane antigen (PSMA) targeting PET imaging has an established role in prostate carcinoma for staging, recurrence evaluation, and selection for PSMA-targeted radiopharmaceutical therapy. We report a case with PSMA avid prostate, hepatic, and osseous lesions in a patient with synchronous malignancies complicating management.

问 AI

Bookmark

View Full Paper

问 AI

Bookmark

View Full Paper

Prostate, Hepatic, and Osseous Lesions on 18F-DCFPyL PET/CT

Key Points

Abstract

Cite This Study

Also Consider

Also Consider